Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Eur J Haematol
    September 2025
  1. CASERTA S, Martino EA, Vigna E, Bruzzese A, et al
    Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
    Eur J Haematol. 2025 Sep 13. doi: 10.1111/ejh.70036.
    >> Share

    July 2025
  2. FUGLKJAER AD, Kilic DK, Eskesen MH, Simonsen MR, et al
    Machine Learning for Prediction of High-Risk Hospitalizations in Lymphoma Patients: A Danish Population-Based Study.
    Eur J Haematol. 2025 Jul 29. doi: 10.1111/ejh.70012.
    >> Share

  3. VAN DER GALIEN HT, Kooistra HAM, Kibbelaar R, Veeger NJGM, et al
    Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months.
    Eur J Haematol. 2025 Jul 9. doi: 10.1111/ejh.70003.
    >> Share

    June 2025
  4. ZHU M, Li T, Han S, Zhao D, et al
    Construction of Lymphoma Organoids and Applications in Tumor Microenvironment Research.
    Eur J Haematol. 2025 Jun 30. doi: 10.1111/ejh.14448.
    >> Share

  5. ROBIN A, Owen C, Perry S, Street L, et al
    Efficacy and Safety of Bendamustine-Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Eur J Haematol. 2025 Jun 1. doi: 10.1111/ejh.14443.
    >> Share

    May 2025
  6. YAGI Y, Kanemasa Y, Sasaki Y, Matsubayashi M, et al
    Site- and Stage-Adapted Treatment Strategies for Gastrointestinal Diffuse Large B-Cell Lymphoma.
    Eur J Haematol. 2025 May 26. doi: 10.1111/ejh.14440.
    >> Share

  7. RU Y, Tong X, Lin J, Chen F, et al
    Learning-Based Classification of B- and T-Cell Lymphoma on Histopathological Images: A Multicenter Study.
    Eur J Haematol. 2025 May 13. doi: 10.1111/ejh.14433.
    >> Share

  8. VON TRESCKOW B, Abrisqueta P, Zamanillo I, Pareja AS, et al
    Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review.
    Eur J Haematol. 2025 May 9. doi: 10.1111/ejh.14423.
    >> Share

    March 2025
  9. LOHRBERG M, Heber M, Ries L, Markus K, et al
    Dual Targeting of Pim and PI3 Kinases in Mature T-Cell Lymphoma.
    Eur J Haematol. 2025 Mar 31. doi: 10.1111/ejh.14420.
    >> Share

  10. MARZOLINI MAV, Kayani I, Carpenter B, Laurence A, et al
    The Effect of the Pre-Transplant Disease Status on the Outcome for Recipients of T-Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell Lymphomas.
    Eur J Haematol. 2025;114:545-555.
    >> Share

    February 2025
  11. CARIDA G, Martino EA, Bruzzese A, Caracciolo D, et al
    Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives.
    Eur J Haematol. 2025 Feb 19. doi: 10.1111/ejh.14401.
    >> Share

  12. TAN XXS, Maltez MT, Mallick R, Hamelin L, et al
    Distance to CAR-T Treatment Center Does Not Impede Delivery.
    Eur J Haematol. 2025;114:276-284.
    >> Share

    January 2025
  13. BENNEDSEN TL, Simonsen MR, Jensen P, Brown P, et al
    Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real-World Setting.
    Eur J Haematol. 2025 Jan 9. doi: 10.1111/ejh.14373.
    >> Share

  14. STRUSSMANN T, Hermes P, Ihorst G, Finke J, et al
    Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients.
    Eur J Haematol. 2025;114:139-146.
    >> Share

    December 2024
  15. PUCKRIN R, Owen C, Peters A
    Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2024 Dec 27. doi: 10.1111/ejh.14376.
    >> Share

  16. BREINHOLT MF, Schejbel L, Gang AO, Christensen IJ, et al
    TP53 Mutation Is the Only Robust Mutational Biomarker for Outcome Found in a Consecutive Clinical Cohort of Real-Word Patients With Primary Large B-Cell Lymphoma.
    Eur J Haematol. 2024 Dec 18. doi: 10.1111/ejh.14364.
    >> Share

  17. METZNER B, Muller TH, Casper J, Kimmich C, et al
    Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma.
    Eur J Haematol. 2024 Dec 10. doi: 10.1111/ejh.14355.
    >> Share

  18. SIMONSEN MR, Jensen JF, Larsen TS, Gade IL, et al
    The Prevalence of Diffuse Large B-Cell Lymphoma Varies Substantially by Methods Applied: Results From a Population-Based Study.
    Eur J Haematol. 2024 Dec 5. doi: 10.1111/ejh.14359.
    >> Share

    November 2024
  19. VIMALATHAS G, Lang CS, Green TM, Moller MB, et al
    Multilevel Analysis of MYC and BCL2 Aberrations in Diffuse Large B-Cell Lymphoma: Identifying a High-Risk Patient Subgroup Across Cell-of-Origin Using Targeted Sequencing.
    Eur J Haematol. 2024 Nov 20. doi: 10.1111/ejh.14345.
    >> Share

  20. GODTFREDSEN SJ, Yonis H, Baech J, Al-Hussainy NR, et al
    Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register-Based Cohort Study.
    Eur J Haematol. 2024 Nov 6. doi: 10.1111/ejh.14334.
    >> Share

    October 2024
  21. MORABITO F, Martino EA, Nizzoli ME, Talami A, et al
    Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma.
    Eur J Haematol. 2024 Oct 27. doi: 10.1111/ejh.14335.
    >> Share

  22. LIEVIN R, Burroni B, Balducci E, Palmic P, et al
    Biological Findings and Clinical Outcomes in Patients Treated With R-CHOP Plus High-Dose Methotrexate as First-Line Therapy in Large B-Cell Lymphoma With Testis Involvement.
    Eur J Haematol. 2024 Oct 12. doi: 10.1111/ejh.14325.
    >> Share

  23. ANDERSEN MD, Wolter K, Enemark MBH, Pedersen MA, et al
    Proteomic Profiling of Lymph Nodes Differentiates Classic Hodgkin Lymphoma With and Without Skeletal Involvement.
    Eur J Haematol. 2024 Oct 11. doi: 10.1111/ejh.14326.
    >> Share

    September 2024
  24. MAZZONI C, Argnani L, Casadei B, Broccoli A, et al
    Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma.
    Eur J Haematol. 2024 Sep 18. doi: 10.1111/ejh.14306.
    >> Share

  25. JELICIC J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, et al
    A Real-World Data-Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B-Cell Lymphoma Patients.
    Eur J Haematol. 2024 Sep 10. doi: 10.1111/ejh.14301.
    >> Share

    July 2024
  26. DILBAZ ZG, Denker S, Ankermann C, Bittenbring JT, et al
    Comparison of R-CHOP-14 and R-mini-CHOP in older adults with diffuse large B-cell lymphoma-A retrospective multicenter cohort study.
    Eur J Haematol. 2024 Jul 31. doi: 10.1111/ejh.14268.
    >> Share

  27. RASK KRAGH JORGENSEN R, Jakobsen LH, Eloranta S, Smedby KE, et al
    Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study.
    Eur J Haematol. 2024 Jul 22. doi: 10.1111/ejh.14275.
    >> Share

    June 2024
  28. WASIFUDDIN M, Ilerhunmwuwa NP, Becerra H, Hakobyan N, et al
    Racial disparities in the incidence and survival outcomes in diffuse large B-cell lymphoma in adolescents and young adults.
    Eur J Haematol. 2024 Jun 18. doi: 10.1111/ejh.14255.
    >> Share

  29. KURTE MS, Siefen AC, Jakobs F, Poos T, et al
    Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.
    Eur J Haematol. 2024 Jun 10. doi: 10.1111/ejh.14248.
    >> Share

  30. KUTSCH N, Godel P, Voltin CA, Hallek M, et al
    Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
    Eur J Haematol. 2024;112:984-987.
    >> Share

    May 2024
  31. VELA-OJEDA J, Olivas-Bejarano AC, Montiel-Cervantes LA, Rosales-Cruz E, et al
    Soluble MIC-A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma.
    Eur J Haematol. 2024 May 14. doi: 10.1111/ejh.14230.
    >> Share

    April 2024
  32. PERNAS B, Iacoboni G, Los-Arcos I, Carpio C, et al
    Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis.
    Eur J Haematol. 2024 Apr 26. doi: 10.1111/ejh.14207.
    >> Share

  33. HARMANEN M, Sorigue M, Khan M, Prusila R, et al
    Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis.
    Eur J Haematol. 2024 Apr 25. doi: 10.1111/ejh.14219.
    >> Share

  34. RICHARDSON T, Scheid C, Herling M, Frenzel LP, et al
    Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trial.
    Eur J Haematol. 2024 Apr 14. doi: 10.1111/ejh.14210.
    >> Share

    March 2024
  35. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
    Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
    Eur J Haematol. 2024;112:371-378.
    >> Share

    February 2024
  36. HEGER JM, d'Hargues Y, Kleinert F, Mattlener J, et al
    Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
    Eur J Haematol. 2024 Feb 18. doi: 10.1111/ejh.14191.
    >> Share

  37. MASSOUD R, Naim H, Klyuchnikov E, Janson D, et al
    Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas.
    Eur J Haematol. 2024;112:276-285.
    >> Share

  38. HO M, Zanwar S, Paludo J
    Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Eur J Haematol. 2024;112:197-210.
    >> Share

    January 2024
  39. YAMAUCHI N, Maruyama D
    Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
    Eur J Haematol. 2024 Jan 3. doi: 10.1111/ejh.14166.
    >> Share

  40. ZEREMSKI V, Adolph L, Beer S, Berisha M, et al
    Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.
    Eur J Haematol. 2024 Jan 2. doi: 10.1111/ejh.14159.
    >> Share

  41. GUPTA S, Kohorst M, Alkhateeb HB
    Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2024;112:51-63.
    >> Share

    December 2023
  42. LOPEZ M, Kainthla R, Lazarte S, Chen W, et al
    Outcomes in Kaposi's sarcoma-associated herpesvirus -associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety-net hospital system.
    Eur J Haematol. 2023 Dec 28. doi: 10.1111/ejh.14163.
    >> Share

  43. RAMDANY H, Lofaro T, Deplano S
    The Haemato-Oncology Frailty (HOF) score to assess frailty in lymphoma.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14152.
    >> Share

  44. MORI T, Osumi T, Kada A, Ohki K, et al
    Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
    >> Share

    October 2023
  45. BREINHOLT MF, Schejbel L, Gang AO, Nielsen TH, et al
    Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.
    Eur J Haematol. 2023;111:583-591.
    >> Share

    September 2023
  46. AGRAWAL V, Murphy L, Pourhassan H, Pullarkat V, et al
    Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 29. doi: 10.1111/ejh.14109.
    >> Share

  47. ZHU H, Zhuang Z, Wang W, Zhao D, et al
    Three cases of late-onset post CAR-T therapy isolated CNS relapse in R/R large B-cell lymphoma.
    Eur J Haematol. 2023 Sep 18. doi: 10.1111/ejh.14078.
    >> Share

  48. CHATTERJEE G, Dhende P, Raj S, Shetty V, et al
    15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14102.
    >> Share

  49. CAI F, Zhang J, Gao H, Shen H, et al
    Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14103.
    >> Share

    July 2023
  50. MATTSSON A, Sylvan SE, Axelsson P, Ellin F, et al
    Idelalisib (PI3Kdelta inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
    Eur J Haematol. 2023 Jul 27. doi: 10.1111/ejh.14065.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016